Eckert & Ziegler with Record Results in FY 2021 and Positive Outlook
Berlin, 30 March 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) achieved sales of EUR 180.4 million in fiscal year 2021 (previous year: EUR 176.1 million). The consolidated net income for the year reached a new record level of EUR 34.5 million (previous year: EUR 22.9 million) or EUR 1.67 per share (previous year: EUR 1.11).
In the Isotope Products segment, sales increased by 7% to EUR 95.8 million. The increase in sales was spread across all product areas.
Due to the deconsolidation of the tumor irradiation business, sales in the Medical segment declined by 2% to EUR 84.5 million. Adjusted for this one-time effect, the segment generated additional sales growth compared to the previous year. The growth driver continues to be the pharmaceutical radioisotope business.
Cash and cash equivalents as of December 31, 2021 amounted to EUR 93.7 million. Compared to the end of 2020, this corresponds to an increase of EUR 6.2 million. As the company continues to operate profitably and self-financing, the Executive Board considers itself well equipped with cash for upcoming growth investments.
For the current fiscal year 2022, the Executive Board expects an increase in sales to around EUR 200 million and a net income of around EUR 38 million. The forecast is based on a weighted average exchange rate of USD 1.20 per EUR and is subject to the assumption that no major disruptions continue to result from the developments in Ukraine.
The Executive Board and Supervisory Board will propose a dividend of EUR 0.50 per dividend-bearing share (previous year: EUR 0.45) to the Annual Shareholders' Meeting.
The full 2021 financial statements can be found here:
www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/deutsch/euzj21e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees, is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
